Navigation Links
Genesis Biopharma to Present at 2011 Biotech Showcase Conference
Date:1/6/2011

MANHATTAN BEACH, Calif., Jan. 6, 2011 /PRNewswire/ -- Genesis Biopharma, Inc. (OTC Bulletin Board: GNBP), a biotechnology company developing targeted cancer therapies, announces that CEO Robert Brooke will present a company overview at the Biotech Showcase™ 2011 conference on Wednesday, January 12, 2011, at 9:45 a.m. Pacific time.  The conference is being held at the Parc 55 Wyndham San Francisco – Union Square.

"We look forward to discussing our progress at this conference, which promotes corporate partnering and attracts an audience interested in companies like Genesis," said Mr. Brooke.  "Last year we took steps to advance development of our proprietary anti-CD55 technology in multiple oncology indications and raised nearly $2 million to support its continued development.  

"We have set an aggressive agenda for 2011.  This quarter we plan to announce results from preclinical efficacy studies with our anti-CD55 therapeutic as a monotherapy in multiple cancer types and in combination with currently marketed blockbuster monoclonal antibodies.  These study results will help us determine the best pathway to advance this program toward clinical proof-of-concept, which typically is shown in Phase 2 clinical trials," he added.

More information about the 2011 Biotech Showcase conference is available at http://www.ebdgroup.com/bts/index.php.

About Genesis Biopharma, Inc.

Genesis Biopharma, Inc. is a development-stage biotechnology company engaged primarily in the development of targeted cancer therapies.  For more information on the company, visit www.genesis-biopharma.com.

The foregoing press announcement contains forward-looking statements that can be identified by such terminology as "expect," "potential," "suggests," "bodes," "may," "should," "could" or similar expressions.  Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements.  In particular, management's expectations regarding future research, development and/or commercial results could be affected by, among other things, uncertainties relating to clinical trials and product development; availability of future financing; unexpected regulatory delays or government regulation generally; the company's ability to obtain or maintain patent and other proprietary intellectual property protection; and competition in general. Forward-looking statements speak only as of the date they are made. The company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.


'/>"/>
SOURCE Genesis Biopharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model
2. Intradigm Study Shows Ability of siRNAs Systemically Delivered With TargeTran(TM) System to Suppress Tumor-Induced Angiogenesis in Mice
3. ADVENTRX to Present ANX-201 Preclinical Data at Keystone Symposia HIV Pathogenesis Conference
4. CorMatrix(R) Announces Intramyocardial Injection of Emulsified ECM Technology(TM) Demonstrates Enhanced Angiogenesis and Improved Cardiac Function in a Preclinical Model
5. Cardiogenesis Announces Preliminary Clinical Results With the PHOENIX System Combining TMR + Stem Cells
6. Neuronascent, Inc. Receives Multiple Fundings for Its Neurogenesis Therapeutic Programs
7. OmegaGenesis Unveils Novel Nanotechnology Platform With Broad Biomedical Applications
8. ThermoGenesis Announces MXP Involvement in New Regenerative Medicine Initiatives
9. Cardiogenesis Announces Presentation of its PHOENIX(R) Combination TMR Plus Stem Cell Delivery System at the International Society of Minimally Invasive Cardiothoracic Surgeons (ISMICS) Annual Meeting
10. ThermoGenesis Announces National Institute of Health Grant
11. Unlikely Treatment Identified by BrainCells Neurogenesis Platform Improved Clinical Outcomes in Patients Suffering From Depression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... 23, 2017 Global Colposcope Market by Manufacturers, ... Colposcope in Global market, especially in North America ... , South America , Middle East ... the market based on manufacturers, regions, type and application. ... Browse 190 Tables and Figures, ...
(Date:3/23/2017)... March 23, 2017   Casetabs , the pioneer ... mobile app for the iPhone. With this new release, ... and communication for physician offices, ambulatory surgery centers (ASCs) ... offers iPhone users even faster, more reliable access to ... even easier to connect care teams so that surgeries ...
(Date:3/23/2017)... , March 23, 2017 ReNeuron ... its CTX cells in chronic stroke patients, despite not meeting ... primary outcome measure, the Action Research Arm Test (ARAT). As ... to a pivotal controlled clinical study in 2017. Beyond CTX, ... (RP) trial in 2017 and Phase I data from its ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... 23, 2017 , ... ChenMed, a privately owned medical, management ... strategic executive team expansion needed to further optimize growth and performance. , “We ... Christopher Chen, MD, ChenMed Chief Executive Officer. “George Wheeler and Donald Trexler ...
(Date:3/23/2017)... ... 2017 , ... Sharon Kleyne, host of the nationally syndicated radio program, The ... recently talked on her program about how she is looking forward to World Water ... an important distinction. World Water Day, Kleyne pointed out, is an occasion for looking ...
(Date:3/23/2017)... Los Angeles, CA (PRWEB) , ... March 23, 2017 , ... ... half of all Americans, yet poor sleep is likely not the only cause of ... these undesirable characteristics that make you look older or in poor health are likely ...
(Date:3/23/2017)... ... March 23, 2017 , ... Natural Subsistence, a ... of people’s health and nutrition, announced its product Leyzene is now available for ... develops nutritional supplements that help people improve all aspects of their health so ...
(Date:3/23/2017)... Square, PA (PRWEB) , ... March 23, 2017 , ... ... days. That means many students are thinking about summer internships , which can ... lack thereof). , The pros at Garden Media Group, a boutique public relations firm ...
Breaking Medicine News(10 mins):